Bayer AG will not pursue development of one its significant cancer therapies, Aliqopa (copanlisib), in diffuse large B-cell lymphoma (DLBCL) despite completing Phase II trials, the company noted in its first quarter financial report for 2018.
Included in Bayer’s Q1 2018 report was a list of “important” pipeline assets currently in Phase II and Phase III...








